The current target therapies for TNBC, such as epidermal growth factor receptor-targeted approach with cetuximab, only demonstrates a modest anti-cancer activity in the metastatic TNBC (40); bevacizumab, which targets vascular endothelial growth factor, does not show a pronounced benefit of overall survival (41). Here, VEGFA is linked to cancer.